Investor Relations

Overview

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta™ (lefamulin), recently approved by the FDA for both Oral and IV use, and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Tuesday November 12, 2019 4:30 PM EST
Nabriva Third Quarter 2019 Financial Results Call

Wednesday October 2, 2019 1:50 PM EDT
2019 Cantor Global Healthcare Conference

Monday September 9, 2019 9:55 AM EDT
Morgan Stanley 17th Annual Global Healthcare Conference

SEC Filings

Filing date Description Form Filing Group View
D
Other
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

A statement of beneficial ownership of common stock by certain persons

SC 13G
3,4,5
View HTML

Investor Contacts

E-mail: IR@nabriva.com